Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
SEER Data: DLBCL Patients at Risk for Second Cancers
Key clinical point: A review of SEER data suggests patients with diffuse large B-cell lymphoma (DLBCL) as a primary cancer are at higher risk for certain second primary malignancies.
Major finding: Among all DLBCL cases identified, 10.95% had a second primary malignancy, with a standardized incidence ratio of 1.19 (P less than .05). The risk for a second cancer was especially high for patients younger than 45 years old.
Study details: A SEER database analysis of 34,254 patients with DLBCL as primary malignancy, including 3,751 patients who had a second primary malignancy.
Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.
Jiang S et al. Curr Probl Cancer. 2019 Sep 9. doi: 10.1016/j.currproblcancer.2019.100502.